

MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) - Pipeline Review, H2 2018

<https://marketpublishers.com/r/MBCF05CC888EN.html>

Date: July 2018

Pages: 41

Price: US\$ 3,500.00 (Single User License)

ID: MBCF05CC888EN

Abstracts

MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) - Pipeline Review, H2 2018

SUMMARY

MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) - MAP kinase-interacting serine/threonine-protein kinase 2 is an enzyme encoded by the MKNK2 gene. It phosphorylates SFPQ/PSF, HNRNPA1 and EIF4E. It plays a role in the response to environmental stress and cytokines. It appears to regulate translation by phosphorylating EIF4E thus increasing the affinity of this protein for the 7-methylguanosine-containing mRNA cap. It triggers EIF4E shuttling from cytoplasm to nucleus. It acts as a mediator of the suppressive effects of IFN γ on hematopoiesis.

MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) pipeline Target constitutes close to 7 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 1 and 2 respectively.

Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Genetic Disorders and Immunology which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Diffuse Large B-Cell Lymphoma,

Fragile X Syndrome, Inflammation, Metastatic Colorectal Cancer and Non-Small Cell Lung Cancer.

The latest report MAP Kinase Interacting Serine/Threonine Protein Kinase 2 - Pipeline Review, H2 2018, outlays comprehensive information on the MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1)

The report reviews MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects

The report assesses MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) - Overview

MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) - Companies Involved in Therapeutics Development

eFFECTOR Therapeutics Inc

Eli Lilly and Co

Merck & Co Inc

Oncodesign SA

MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) - Drug Profiles

cercosporamide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

eFT-508 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ETC-17804452 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit MAPKAP Kinase 2 for Inflammation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit MKNK1 and MKNK2 for Oncology and Unspecified Indication - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit MNK1 and MNK2 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Mnk2 for Acute Myeloid Leukemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) - Dormant Products

MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) - Product Development Milestones

Featured News & Press Releases

Jun 06, 2018: eFFECTOR Initiates Dosing of eFT508 in Phase 2 Expansion of Clinical Trial in Aggressive Form of Non-Hodgkin's Lymphoma

May 11, 2018: eFFECTOR Initiates Randomized Dosing in Phase 2 Checkpoint Combination Trial of eFT508 and Avelumab in Colorectal Cancer

Apr 26, 2018: eFFECTOR Publishes the Design and Profile of eFT508 in Peer Reviewed Journal of Medicinal Chemistry

Apr 16, 2018: eFFECTOR to Present Data on eFT508 at the AACR 2018 Annual Meeting

Dec 11, 2017: Clinical Data for eFFECTOR Therapeutics' Lead Candidate eFT508 Demonstrates Clinical Activity, Well-Tolerated Safety Profile

Dec 05, 2017: Oncodesign Reports Positive Results for Its MNK1/2 Program

Nov 10, 2017: eFFECTOR Therapeutics Presents Preclinical Data for eFT508 that Demonstrates Beneficial Immunological Effects

Oct 04, 2017: eFFECTOR Therapeutics Initiates Dosing in Phase 2 Combination Trial of eFT508 and Avelumab in Microsatellite Stable Colorectal Cancer

Jun 05, 2017: eFFECTOR Therapeutics Presents Phase 1 Data On eFT508, Its Lead Product Candidate, At ASCO 2017

Apr 10, 2017: Cancer Genetics is Selected by eFFECTOR Therapeutics to Provide Biomarker Discovery and Development Services for Novel Oncology Drugs

Apr 03, 2017: eFFECTOR Therapeutics Presents Positive Preclinical Data on Lead Product Candidate at AACR 2017

Mar 09, 2017: Effector Therapeutics Lead Product Candidate, EFT508, Receives Orphan Designation From FDA for Treatment of Diffuse Large B-cell Lymphoma

Mar 18, 2016: eFFECTOR Therapeutics to Present at the American Association for Cancer Research 2016 Annual Meeting

Jun 19, 2015: Peer-Reviewed Study in Cell Validates eFFECTOR Therapeutics' Novel Small-Molecule Approach to Cancer Treatment

Jan 06, 2015: eFFECTOR Therapeutics Initiates Dosing in Phase 1/2 Clinical Trial of eFT508 in Solid Tumors

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by eFFECTOR Therapeutics Inc, H2 2018
Pipeline by Eli Lilly and Co, H2 2018
Pipeline by Merck & Co Inc, H2 2018
Pipeline by Oncodesign SA, H2 2018
Dormant Projects, H2 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

COMPANIES MENTIONED

eFFECTOR Therapeutics Inc

Eli Lilly and Co

Merck & Co Inc

Oncodesign SA

I would like to order

Product name: MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) - Pipeline Review, H2 2018

Product link: <https://marketpublishers.com/r/MBCF05CC888EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/MBCF05CC888EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

